NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN) today reported preclinical data demonstrating positive immunogenicity and lack of immune interference for an experimental single-dose, oral vaccine combining protection from three of the most important causes of severe enteric diseases: typhoid fever, enterotoxigenic E. coli (ETEC) and cholera. The experimental, trivalent vaccine consists of the co-administration of two live-attenuated bacteria: the Peru-15pCTB vaccine candidate that forms the basis of AVANT’s investigational combination ETEC/cholera vaccine and AVANT’s investigational typhoid fever vaccine, Ty800.
